Examkin

Question

Difficulty: Very hardInfectious Diseases

A 68-year-old man is admitted to the hospital with a 3-week history of low-grade fever, fatigue, and progressive dyspnea on exertion. His medical history is significant for hypertension, type 2 diabetes mellitus, and stage 4 chronic kidney disease with a baseline serum creatinine of 2.8 mg/dL. His temperature is 38.2°C (100.8°F), blood pressure is 132/78 mmHg, and heart rate is 96/min. Physical examination reveals a new grade 3/6 holosystolic murmur heard best at the cardiac apex and radiating to the axilla. Small, dark red linear streaks are noted under the nail beds of both hands. A transesophageal echocardiogram demonstrates a 1.2-cm mobile vegetation on the posterior leaflet of the mitral valve with moderate mitral regurgitation. Three sets of blood cultures drawn 12 hours apart all grow *Enterococcus faecalis*. Antimicrobial susceptibility testing shows the isolate is susceptible to ampicillin, vancomycin, daptomycin, linezolid, and high-level gentamicin. Which of the following is the most appropriate definitive intravenous pharmacotherapy for this patient?

  1. Ampicillin and ceftriaxoneAnswer
  2. B
    Ampicillin and gentamicin
  3. C
    Vancomycin and gentamicin
  4. D
    Ampicillin monotherapy
  5. E
    Daptomycin monotherapy

Answer

The most appropriate definitive therapy is the combination of ampicillin and ceftriaxone.
The correct answer is the combination of ampicillin and ceftriaxone. Enterococcus faecalis infective endocarditis strictly requires a bactericidal synergistic therapy regimen for a definitive cure. Traditionally, this was achieved by combining a cell wall-active agent (such as ampicillin) with an aminoglycoside (such as gentamicin). However, aminoglycosides carry a well-documented risk of dose-dependent nephrotoxicity, making them exceptionally hazardous in patients with preexisting severe renal impairment, such as this patient with stage 4 chronic kidney disease. A highly effective, alternative synergistic regimen is double beta-lactam therapy using ampicillin and ceftriaxone. Although enterococci are intrinsically resistant to cephalosporins, ceftriaxone uniquely saturates specific complementary penicillin-binding proteins (PBPs 2 and 3). This synergizes perfectly with ampicillin, which binds PBPs 1, 4, and 5. The dual-binding mechanism achieves complete bactericidal activity equivalent to the ampicillin-gentamicin combination while entirely avoiding the risk of aminoglycoside-induced renal failure.

Step-by-Step Solution

1
Identify the primary diagnosis based on the clinical presentation.
The patient has native valve infective endocarditis caused by Enterococcus faecalis, indicated by subacute fever, a new mitral murmur, splinter hemorrhages, echocardiographic evidence of a vegetation, and positive blood cultures.
Establishing the diagnosis and the responsible pathogen is necessary to guide targeted antimicrobial therapy.
2
Determine the therapeutic requirements for curing enterococcal endocarditis.
Enterococci are uniquely tolerant to cell wall-active agents; therefore, a bactericidal synergistic combination regimen is strictly required for clinical cure.
Monotherapy is purely bacteriostatic against enterococci and will result in clinical failure or relapse.
3
Analyze the patient's specific comorbidities that impact pharmacological choices.
The patient has advanced (stage 4) chronic kidney disease with a significantly elevated baseline creatinine of 2.8 mg/dL.
Severe renal impairment is an absolute contraindication for nephrotoxic medications if safer, equally effective alternatives exist.
4
Select the optimal synergistic regimen that maximizes efficacy while minimizing toxicity.
Ampicillin combined with ceftriaxone is selected over ampicillin combined with gentamicin to prevent aminoglycoside-induced acute kidney injury.
The double beta-lactam regimen provides equivalent synergistic bactericidal activity through complementary binding of penicillin-binding proteins, without the nephrotoxic profile of aminoglycosides.

Key Concept

Treatment of Enterococcus faecalis infective endocarditis in patients with high risk of nephrotoxicity.
Rate this question

Topics

Infectious Diseases

More questions from this topic